



UNITAID Executive Board Meeting
 19th Session
 12 - 13 December 2013
 CCV, Salle A
 Geneva, Switzerland

Resolution n°5

WHO Prequalification of Medicines and Diagnostics

“Increased access to appropriate, quality-assured diagnostics, medical devices and medicines for prevention, initiation and treatment of HIV/AIDS, TB and malaria”

Recognizing the on-going organizational changes being made by the World Health Organization (WHO) to promote a functional approach to the regulation of medical products and technologies, leading to a single, transparent policy on prequalification, harmonization of national regulatory strengthening and, among all product streams, greater efficiency through common support, oversight and performance structures and the sharing of best practices;

Taking into account the outcome of the PRC review of 14 November 2013, of the proposal submitted to UNITAID by WHO for the project: *Increased access to appropriate, quality-assured diagnostics, medical devices and medicines for prevention, initiation and treatment of HIV/AIDS, TB and malaria*;

The Board of UNITAID, subject to the availability of funds, authorizes the Executive Director to commit up to **USD 50,303,408** for the aforementioned project.

Lead organization(s): WHO Prequalification Programme (WHO/PQ)

Lead recipient: WHO Prequalification Programme (WHO/PQ)

- For Medicines Prequalification Project (MPQ): **USD 38,136,728**
- For Diagnostics Prequalification Project (DxPQ): **USD 12,166,680**

Project Duration: Three (3) years for each Project from date of Grant Agreement Signature

Conditions for UNITAID funding support:

Funding is conditional upon:

1. Development of a clear, focused, prioritized and results-oriented implementation plan for each project;
2. Strict alignment of all outputs, for each project, with UNITAID’s Strategic Objectives and its catalytic, time-limited focus;

3. Satisfactory responses being provided to the Secretariat to the issues raised by the PRC and Secretariat proposal reviews;
4. For the DxPQ Project, finalization and launch of the Expert Review Panel for Diagnostics by Q2 2014, as an expedited assessment route for new, priority products reaching the market;
5. Signature of two separate legal agreements between WHO and UNITAID i.e. one for each project.

A handwritten signature in blue ink, appearing to read 'P. Douste-Blazy'.

Philippe Douste-Blazy
Chair of the UNITAID Executive Board